Patents by Inventor Jon R. Polansky
Jon R. Polansky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7138511Abstract: In a preferred aspect of the invention, the upstream sequences of the TIGR protein encoding sequence can be used to diagnose a sensivity to steroids and a risk for glaucoma or ocular hypertensive disorders. Methods, kits, and nucleic acids containing polymorphisms, base substitutions, or base additions located within the upstream region and within protein-encoding regions of the TIGR gene are also provided. The upstream sequences disclosed, including the TIGR promoter regions and those regions possessing functional characterisitics associated with or possesssed by the TIGR gene 5?regulatory region, can also be used to generate cells, vectors, and nucleic acids useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions, and methods.Type: GrantFiled: January 11, 1999Date of Patent: November 21, 2006Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Pu Chen, Hua Chen
-
Publication number: 20030068640Abstract: In a preferred aspect of the invention, the upstream sequences of the TIGR protein encoding sequence can be used to diagnose a sensivity to steroids and a risk for glaucoma or ocular hypertensive disorders. Methods, kits, and nucleic acids containing polymorphisms, base substitutions, or base additions located within the upstream region and within protein-encoding regions of the TIGR gene are also provided. The upstream sequences disclosed, including the TIGR promoter regions and those regions possessing functional characteristics associated with or possessed by the TIGR gene 5′regulatory region, can also be used to generate cells, vectors, transgenic animals, and nucleic acid constructs useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions, and methods.Type: ApplicationFiled: September 17, 2002Publication date: April 10, 2003Inventors: Thai D. Nguyen, Jon R. Polansky, Pu Chen, Hua Chen
-
Patent number: 6475724Abstract: In a preferred aspect of the invention, the upstream sequences of the TIGR protein encoding sequence can be used to diagnose a sensivity to steroids and a risk for glaucoma or ocular hypertensive disorders. Methods, kits, and nucleic acids containing polymorphisms, base substitutions, or base additions located within the upstream region and within protein-encoding regions of the TIGR gene are also provided. The upstream sequences disclosed, including the TIGR promoter regions and those regions possessing functional characteristics associated with or possessed by the TIGR gene 5′regulatory region, can also be used to generate cells, vectors, transgenic animals, and nucleic acid constructs useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions, and methods.Type: GrantFiled: May 7, 1999Date of Patent: November 5, 2002Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Pu Chen, Hua Chen
-
Patent number: 6248867Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: October 20, 1995Date of Patent: June 19, 2001Inventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 6171788Abstract: The nucleic acid upstream of the TIGR protein encoding sequence can be used to diagnose glaucoma. Polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to diagnose glaucoma. In addition, polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to prognose glaucoma.Type: GrantFiled: September 26, 1997Date of Patent: January 9, 2001Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Pu Chen, Hua Chen
-
Patent number: 6150161Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: December 24, 1998Date of Patent: November 21, 2000Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5861497Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: June 21, 1996Date of Patent: January 19, 1999Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5854415Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabeclar meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: June 25, 1997Date of Patent: December 29, 1998Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5849879Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: May 14, 1996Date of Patent: December 15, 1998Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5789169Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related disease.Type: GrantFiled: May 17, 1996Date of Patent: August 4, 1998Assignee: Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5674888Abstract: The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e.g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treat loss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non-steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.Type: GrantFiled: June 7, 1995Date of Patent: October 7, 1997Assignee: University of CaliforniaInventors: Jon R. Polansky, Ernest Bloom, Donald J. Fauss
-
Patent number: 5606043Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: November 3, 1994Date of Patent: February 25, 1997Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5599535Abstract: The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.Type: GrantFiled: June 7, 1995Date of Patent: February 4, 1997Assignee: Regents of the University of CaliforniaInventors: Jon R. Polansky, Ernest Bloom, Donald J. Fauss
-
Patent number: 5538721Abstract: The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; and methods for stabilizing and solubilizing amino-substituted steroid therapeutic agents in such pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers and amounts of selected cyclodextrin derivatives sufficient to at least partially solubilize the therapeutic agents. The cyclodextrin derivatives are selected from the group consisting of the hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclodextrin. Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.Type: GrantFiled: February 28, 1994Date of Patent: July 23, 1996Assignee: InSite Vision IncorporatedInventors: John C. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C. C. Si, Santosh K. Chandrasekaran
-
Patent number: 5474985Abstract: Methods and compositions for preventing or treating non-inflammatory elevated intraocular pressure associated with administered or endogenous steroids including administering to a mammalian organism a composition including (a) an ophthalmologically effective amount of a non-steroidal cyclooxygenase inhibitor, and (b) a pharmaceutically acceptable carrier, to reduce or prevent an elevation of intraocular pressure and/or protein marker induction induced by chronic exposure to glucocorticoids.Type: GrantFiled: December 22, 1993Date of Patent: December 12, 1995Assignee: The Regents of the University of CaliforniaInventors: Jon R. Polansky, Ernest Bloom, Donald J. Fauss
-
Patent number: 5332582Abstract: The invention provides methods for stabilizing amino-substituted steroid therapeutic agents in topical ophthalmic and other pharmaceutical formulations using effective stabilizing amounts of lightly cross-linked carboxy-containing polymers; Stabilized and stabilized/solubilized pharmaceutical compositions adapted for various routes of administration are also described.Type: GrantFiled: December 2, 1992Date of Patent: July 26, 1994Assignee: Insite Vision IncorporatedInventors: John C. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C. Si, Santosh K. Chandrasekaran
-
Patent number: 5256408Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.Type: GrantFiled: February 19, 1992Date of Patent: October 26, 1993Assignee: Insite Vision IncorporatedInventors: John G. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C. Si, Santosh K. Chandrasekaran
-
Patent number: 5252319Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.Type: GrantFiled: February 19, 1992Date of Patent: October 12, 1993Assignee: Insite Vision IncorporatedInventors: John C. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C.-C. Si, Santosh K. Chandrasekaran
-
Patent number: 5209926Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.Type: GrantFiled: August 24, 1992Date of Patent: May 11, 1993Assignee: InSite Vision IncorporatedInventors: John C. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C. Si, Santosh K. Chandrasekaran
-
Patent number: 5124154Abstract: Methods and compositions for preventing or treating ophthalmic diseases or disorders wherein an ophthalmically effective amount of the C.sub.20 through C.sub.26 aminosteroids of formula XI and their pharmaceutical, acceptable salts, hydrates or solvates is administered in an inert vehicle to arrest oxidation processes damaging to the eye.Type: GrantFiled: June 12, 1990Date of Patent: June 23, 1992Assignee: InSite Vision IncorporatedInventors: John C. Babcock, Jon R. Polansky, Lyle M. Bowman, Sheng-Wan Tsao, Erwin C. Si, Santosh K. Chandrasekran